Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases
AssigneesThe Johns Hopkins University, Wake Forest University
InventorsEsther Oh, Constantine Lyketsos, Suzanne Craft
Life of this patent
Estimating the term…
Abstract
Described herein are methods of identifying a mammal having a neurological disease or disorder, such as AD or MCI, or at risk for developing a neurological disease or disorder, such as AD or MCI. Provided herein are also methods of monitoring the progression of a neurological disease or disorder in a patient or monitoring the effectiveness of therapeutic agent or treatment of a patient having a neurological disease or disorder.
Claims21
A method of identifying a mammal having a neurological disease or disorder, or at risk for developing a neurological disease or disorder, comprising:
- a) obtaining a biological sample from the mammal;
- b) subjecting the mammal to a glucose tolerance test (GTT);
- c) obtaining a biological sample from the mammal after GTT;
- d) determining the level of expression or level of activity, or change in level of expression or activity before and after GTT of one or more biomarkers selected from Aβ 40, Aβ 42, and both, in the mammal sample;
- e) determining the level of expression or level of activity, or change in level of expression or activity before and after GTT of said one or more biomarkers in a standard control;
- and
- f) comparing the level of expression or level of activity, or change in level of expression or activity before and after GTT of said one or more biomarkers determined in steps c) and d);
- wherein modulation in the level of expression or level of activity, or change in level of expression or activity before and after GTT of the one or more biomarkers in the mammal sample relative to the standard control level of expression or level of activity, or change in level of expression or activity before and after GTT of the one or more biomarkers indicates that the mammal is afflicted with a neurological disorder, or at risk of developing a neurological disorder.
10-30. (canceled)
A method for monitoring the progression of a neurological disease or disorder in a patient or monitoring the effectiveness of a therapeutic agent or treatment of a patient having a neurological disease or disorder, the method comprising:
- (i) obtaining a pre-administration sample from a patient prior to administration of the therapeutic agent or treatment;
- (ii) subjecting the patient to OGTT;
- (iii) detecting the levels of one or more biomarkers in the pre-administration sample;
- (iv) obtaining one or more post-administration samples from the patient;
- (v) detecting the change in the levels of one or more biomarkers in the post-administration samples;
- (vi) comparing the level of one of more biomarkers in step (iii) pre-administration sample with the level of one of more biomarkers in step (v) in the post-administration sample or samples;
- and
- (vii) altering the treatment of the patient.
Dependencies are inferred from the claim text.